Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tourmaline Bio

18.80
+1.7610.33%
Post-market: 17.86-0.9400-5.00%19:52 EDT
Volume:628.22K
Turnover:11.49M
Market Cap:482.08M
PE:-6.74
High:18.82
Open:17.72
Low:17.53
Close:17.04
Loading ...

Analysts’ Top Healthcare Picks: Neumora Therapeutics, Inc. (NMRA), Tourmaline Bio (TRML)

TIPRANKS
·
22 Nov 2024

Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024

GlobeNewswire
·
14 Nov 2024

Tourmaline Bio, Inc. Reports Third Quarter Financial Results

TIPRANKS
·
12 Nov 2024

Tourmaline Bio Inc : H.c. Wainwright Raises Target Price to $49 From $48

THOMSON REUTERS
·
12 Nov 2024

Tourmaline Bio Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
12 Nov 2024

Tourmaline Bio price target raised to $49 from $48 at H.C. Wainwright

TIPRANKS
·
12 Nov 2024

Tourmaline Bio’s Promising Clinical Developments and Financial Stability Underpin Buy Rating

TIPRANKS
·
11 Nov 2024

BRIEF-Tourmaline Bio Inc Files For Mixed Shelf Of Up To $350 Million - SEC Filing

Reuters
·
08 Nov 2024

Tourmaline Bio Inc Files for Mixed Shelf of up to $350 Mln - SEC Filing

THOMSON REUTERS
·
08 Nov 2024

Tourmaline Bio Q3 2024 GAAP EPS $(0.78) Beats $(0.84) Estimate, Cash, Cash Equivalents And Investments Of $314.4M, Providing Cash Runway Into 2027

Benzinga
·
07 Nov 2024

Tourmaline Bio Inc: Qtrly Loss per Share $0.78

THOMSON REUTERS
·
07 Nov 2024

Press Release: Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Dow Jones
·
07 Nov 2024

Tourmaline Bio: Unlocking Value through Promising IL-6 Inhibition Strategy in ASCVD Treatment

TIPRANKS
·
05 Nov 2024

Truist Financial Keeps Their Buy Rating on Tourmaline Bio (TRML)

TIPRANKS
·
04 Nov 2024

Tourmaline Bio initiated with an Overweight at Cantor Fitzgerald

TIPRANKS
·
15 Oct 2024

Cantor Fitzgerald Initiates Tourmaline Bio at Overweight

MT Newswires Live
·
15 Oct 2024